Zhuhai Tongyuan Pharmaceutical

Zhuhai Tongyuan Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Zhuhai, China, dedicated to the development of next-generation small molecule targeted therapies for cancer. The company focuses on addressing clinical resistance in oncology by designing highly selective inhibitors for targets such as ROS1, ALK, CDK4/6, and EGFR. Its lead program, TY-2136, is a potent ROS1/ALK inhibitor currently in Phase 2 clinical trials for patients with non-small cell lung cancer. Tongyuan Pharmaceutical aims to provide effective precision medicine solutions for patients with advanced malignancies through its robust internal research and development platform. The company is led by a team of experienced scientists with a track record in global drug development.